{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:33:31Z","timestamp":1736400811656,"version":"3.32.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1718","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Isatuximab-irfc (Sarclisa \u2013 Sanofi), a CD38-directed cytolytic antibody, has been approved by the FDA for treatment of newly diagnosed multiple myeloma in adults who are not eligible for autologous stem cell transplantation (ASCT). The drug was approved earlier for treatment of relapsed or treatment-refractory multiple myeloma.<\/jats:p>","DOI":"10.58347\/tml.2024.1717e","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:08:41Z","timestamp":1736381321000},"page":"e200-e201","source":"Crossref","is-referenced-by-count":0,"title":["Isatuximab (Sarclisa) for Multiple Myeloma"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,12,9]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:08:41Z","timestamp":1736381321000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1717e"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":0,"journal-issue":{"issue":"1718","published-online":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1717e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}